Live prices from 2 SA suppliers, from R500.00, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Compare 2 prices for Cerebrolysin. Cheapest: R500.00. Average: R574.50.
| Compare | Visit | |||||||
|---|---|---|---|---|---|---|---|---|
Crono Pharm
Best
Cerebrolysin 60mg |
R500.00 | R8.33/mg | Out of Stock | R150.00 |
Lab Tested
|
— | ||
|
Cerebrolysin Pen |
R649.00 | R10.82/mg | Out of Stock | Free over R600 |
Lab Tested
|
— |
More ways to compare Cerebrolysin
Different views of the same live SA pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
Neuropeptide Preparation | Neurological Recovery
Standardized neuropeptide preparation containing bioactive peptides and amino acids exhibiting neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement. Used clinically in 50+ countries.
IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors.
Bioactive peptide mixture
Meta-analyses show modest cognitive improvements, though clinical significance remains debated.
Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements.
Large meta-analysis shows significant NIHSS improvements; other studies found no functional benefit.
Largest meta-analysis (1,879 patients) shows NIHSS benefits; independent analysis found no mRS improvement.
Multiple trials including CAPTAIN series confirm GCS/GOS improvements.
Pilot trial shows promising 6-month outcomes; requires larger confirmatory studies.
Some studies show enhanced recovery; results vary significantly between trials.
Early administration within 72 hours shows better outcomes than delayed treatment.
Primary administration route with well-established protocols for direct brain delivery via IV/IM.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Small Volume IV | Up to 10mL | Once daily | Undiluted IV slow push over 3 minutes |
| Intramuscular | Up to 5mL | Once daily | Undiluted IM injection over 3 minutes |
| Acute Stroke | 20-50mL | Once daily for 10-21 days | IV infusion (diluted to 100mL minimum) |
| Traumatic Brain Injury | 20-50mL | Once daily for 7-30 days | IV infusion (diluted to 100mL minimum) |
| Alzheimer's Disease | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
| Vascular Dementia | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
Safe combination with no significant interactions; both support cognitive function.
No interactions reported; may have synergistic cognitive effects in Alzheimer's treatment.
Potential additive neurotropic effects; monitor for enhanced antidepressant effects.
May have additive neurological effects; requires careful monitoring.
Contraindicated per prescribing information; do not mix in same infusion.
Should not be mixed in same IV infusion per official guidelines.
Compatibility issues; do not mix in same IV infusion.
Both enhance neurotrophic factors; potential additive effects—start with lower doses.
Initial neuroprotective effects; possible mild side effects (dizziness, agitation)
Neurological improvements become apparent; cognitive function may begin to improve
Continued recovery; motor function improvements in stroke/TBI patients
Sustained benefits; cognitive enhancement plateaus in chronic conditions
Randomized controlled trial demonstrating efficacy and safety in moderate-severe TBI with improved GCS and GOS scores.
Largest positive meta-analysis showing significant neurological improvements in 1,879 stroke patients with NNT=7.7.
Independent meta-analysis of 1,779 patients found no significant benefits in functional outcomes (mRS/BI).
Analysis of 8,749 TBI patients across 10 studies confirms statistically significant GCS/GOS improvements.
Be the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.